Neuren Pharmaceuticals has secured European Commission marketing authorisation for its flagship drug Daybu (trofinetide), making it the first and only approved treatment for Rett syndrome across all 27 European Union member states, plus Iceland, Liechtenstein, and Norway, for patients aged five years and older.
The regulatory decision creates a new therapeutic option for families managing a severe neurodevelopmental disorder that has lacked approved pharmacological interventions in Europe. Acadia Pharmaceuticals, which holds the exclusive worldwide licence to develop and commercialize trofinetide, anticipates launching the oral solution in Germany in early in the fourth quarter of 2026. This approval also triggers financial milestones for Melbourne-based Neuren under its licensing agreement.
In Plain English: The Clinical Takeaway
- Target Population: Daybu is authorized for patients aged five years and older diagnosed with Rett syndrome, addressing neurobehavioural symptoms.
- Mechanism and Delivery: Administered as an oral solution, trofinetide is designed to mitigate the profound neurological impairments associated with this genetic condition.
- Access Timeline: Following the European Commission green light, commercial availability will roll out regionally, starting with Germany in early in the fourth quarter of 2026.
Regulatory Milestone and European Market Expansion
The European Commission’s marketing authorisation marks a milestone for the global commercialization of trofinetide. The green light extends access across all 27 EU member states, alongside Iceland, Liechtenstein, and Norway. For a rare genetic condition that predominantly affects girls and causes severe impairments in communication, motor function, and everyday functioning, this decision brings a new treatment option to a previously underserved patient population.
Chief executive Jon Pilcher highlighted what the regulatory clearance means for families across Europe, stating that “We are delighted for the Rett syndrome community in Europe, who, until now, have had no approved treatment for this devastating condition.” Pilcher further noted that the green light is “particularly rewarding for Neuren given our long-standing commitment to developing therapies for serious neurological disorders with profound unmet need.”
Financial Architecture and Commercial Licensing
Beyond its clinical impact, the European authorization carries financial weight for Neuren Pharmaceuticals. Under the terms of the regional licence agreement, Acadia Pharmaceuticals will pay Neuren US$35 million following the first commercial sale of Daybu within Europe. In addition, Neuren stands to receive up to US$170 million in sales milestone payments as yearly net sales hit higher tiers, along with tiered royalties spanning from the mid-teens to the low 20 per cent bracket.
Acadia holds the exclusive worldwide licence to develop and commercialize the drug, having already launched Daybue oral solution in the United States, Canada, and Israel, alongside FDA approvals for DAYBUE STIX powder. Trofinetide remains unapproved for commercial sale in Australia.
Broader Clinical Pipeline and Ongoing Trials
Neuren continues to advance its clinical pipeline targeting other serious rare neurodevelopmental disorders beyond Rett syndrome. The company’s investigational candidate, NNZ-2591 (also known as ercanetide), is currently undergoing clinical evaluation across multiple complex conditions. These include Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Angelman syndrome.
Additionally, Neuren is investigating NNZ-2591 as a therapeutic intervention for hypoxic ischaemic encephalopathy, a form of brain injury occurring before or shortly after birth. The company is actively executing its Phase 3 Koala trial—a randomized, double-blind, and placebo-controlled study assessing NNZ-2591 in pediatric patients aged three to 12 years with Phelan-McDermid syndrome—paired with a 52-week open-label extension study.
Contraindications & When to Consult a Doctor
As with all targeted neurological therapies, prescribing decisions require careful clinical evaluation. Patients and caregivers should consult a qualified pediatric neurologist or metabolic specialist to review individual patient eligibility, potential gastrointestinal or behavioral side effects, and exact dosing protocols for the oral solution. Medical supervision is essential to manage contraindications, monitor therapeutic response, and align treatment plans with established clinical guidelines.
